Facilitating COVID-19 Vaccine Trial Success

The global coronavirus outbreak prompted the need for accelerated clinical development of a novel vaccine. 

Signant partnered with a leading global pharmaceutical sponsor to overcome unprecedented challenges including: 

• Overlapping protocol phases
• Navigating safety restrictions and precautions
• Delivering and managing 40,000 provisioned devices 
• Capturing reactogenicity, safety, and efficacy data from 45,000 participants across more than 100 sites around the globe

Download this case study to learn how Signant's eCOA solutions and global operational expertise helped the sponsor launch the study in just five weeks, capture high-quality endpoint data, and achieve Emergency Use Authorization followed by full FDA approval.